Status:
UNKNOWN
Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs
Lead Sponsor:
Assiut University
Conditions:
HCV
Eligibility:
All Genders
18+ years
Brief Summary
1. Study Changes in lipid profile and the impact of Insulin resistance on virological response in patients with Hepatitis C viral infection treated by Direct Acting Antiviral agents 2. The assessment ...
Detailed Description
Patients and methods: This cross-sectional study will include 100patients of chronic HCV infection who attend El Raghy Assiut university Hospital, either inpatients or outpatients. Chronic HCV infect...
Eligibility Criteria
Inclusion
- Chronic HCV will receive DAAs for treatment
Exclusion
- Decompensated liver cirrhosis, hepatocellular carcinoma, history of liver transplant
- Co-existing liver disease (hepatitis B virus, autoimmune hepatitis, human immunodeficiency virus)
- Extra-hepatic malignancy except after two years of disease free interval.
- Patients with diabetes mellitus.
- Patients with Chronic kidney disease.
- Pregnancy or in ability to use effective contraception.
- Patients with history of using lipid lowering therapy
- relapser or failure of previous HCV treatment
Key Trial Info
Start Date :
March 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03820102
Start Date
March 1 2019
End Date
October 1 2019
Last Update
February 5 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.